Overexpression of MPS antigens by squamous cell carcinomas of the head and neck immunohistochemical and serological correlation with FDG positron emission tomography

Brendan C. Stack, Thomas A. Dalsaso, Christopher Lee, Val J. Lowe, Paul D. Hamilton, James Fletcher, J. Albert Fernandez-Pol

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Survival from advanced primary or recurrent Squamous Cell Carcinoma (SCC) of the head and neck (H and N) is poor. More accurate defection of primary tumors and recurrence may provide ways to improve survival. No standard serum tumor marker is routinely used for surveillance of SCC-H and N. In this paper, we evaluated the performance characteristics of the MPS-H tumor marker test for the quantitative measurement of 'MPS-H' heat-generated immunoreactive proteins and assessed the clinical utility of this marker in the detection and monitoring of SCC-H and N. In approximately 92% of the subjects having no evidence of SCC-H and N, the MPS-H levels were lower than 15 ng/mL. In 76% of patients having SCC-H and N at various stages (T1-T4) the MPS-H level was > 15 ng/ml (range: 20-200 ng/mL). In addition, we found a statistically significant correlation between PET positive cases and high MPS-H serum levels in SCC-H and N patients with recurrent disease. These results suggest that MPS-H may provide an initial screening test that would allow for selective PET imaging in these patients. Furthermore, we found that there was greater expression of MPS-1 in tumors of higher histological grades. Thus, in tumors with more histological agressiveness there is more MPS-I, indicating the potential usefulness of this marker in prognosis for SSC-H and N. Considering the immunohistochemical, serological, and FDG-PET data presented here, and the compelling need to expedite the early diagnosis of primary and recurrent epithelial malignancies of the head and neck, we are further evaluating the system of MPS antigens in a large patient population as a tool for the early serologic and histologic diagnosis of SCC-H and N.

Original languageEnglish (US)
Pages (from-to)5503-5510
Number of pages8
JournalAnticancer Research
Volume19
Issue number6 C
StatePublished - 1999
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Antigens
Squamous Cell Carcinoma
Tumor Biomarkers
Neoplasms
Biomarkers
Survival
Early Diagnosis
Neck
Hot Temperature
Head
Recurrence
Carcinoma, squamous cell of head and neck
Serum
Population
Proteins

Keywords

  • Metallopanstimulin
  • Ribosomal S27 protein
  • Tumor markers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Overexpression of MPS antigens by squamous cell carcinomas of the head and neck immunohistochemical and serological correlation with FDG positron emission tomography. / Stack, Brendan C.; Dalsaso, Thomas A.; Lee, Christopher; Lowe, Val J.; Hamilton, Paul D.; Fletcher, James; Fernandez-Pol, J. Albert.

In: Anticancer Research, Vol. 19, No. 6 C, 1999, p. 5503-5510.

Research output: Contribution to journalArticle

Stack, Brendan C. ; Dalsaso, Thomas A. ; Lee, Christopher ; Lowe, Val J. ; Hamilton, Paul D. ; Fletcher, James ; Fernandez-Pol, J. Albert. / Overexpression of MPS antigens by squamous cell carcinomas of the head and neck immunohistochemical and serological correlation with FDG positron emission tomography. In: Anticancer Research. 1999 ; Vol. 19, No. 6 C. pp. 5503-5510.
@article{67970021573e4a6f9b5923c0d2ba686a,
title = "Overexpression of MPS antigens by squamous cell carcinomas of the head and neck immunohistochemical and serological correlation with FDG positron emission tomography",
abstract = "Survival from advanced primary or recurrent Squamous Cell Carcinoma (SCC) of the head and neck (H and N) is poor. More accurate defection of primary tumors and recurrence may provide ways to improve survival. No standard serum tumor marker is routinely used for surveillance of SCC-H and N. In this paper, we evaluated the performance characteristics of the MPS-H tumor marker test for the quantitative measurement of 'MPS-H' heat-generated immunoreactive proteins and assessed the clinical utility of this marker in the detection and monitoring of SCC-H and N. In approximately 92{\%} of the subjects having no evidence of SCC-H and N, the MPS-H levels were lower than 15 ng/mL. In 76{\%} of patients having SCC-H and N at various stages (T1-T4) the MPS-H level was > 15 ng/ml (range: 20-200 ng/mL). In addition, we found a statistically significant correlation between PET positive cases and high MPS-H serum levels in SCC-H and N patients with recurrent disease. These results suggest that MPS-H may provide an initial screening test that would allow for selective PET imaging in these patients. Furthermore, we found that there was greater expression of MPS-1 in tumors of higher histological grades. Thus, in tumors with more histological agressiveness there is more MPS-I, indicating the potential usefulness of this marker in prognosis for SSC-H and N. Considering the immunohistochemical, serological, and FDG-PET data presented here, and the compelling need to expedite the early diagnosis of primary and recurrent epithelial malignancies of the head and neck, we are further evaluating the system of MPS antigens in a large patient population as a tool for the early serologic and histologic diagnosis of SCC-H and N.",
keywords = "Metallopanstimulin, Ribosomal S27 protein, Tumor markers",
author = "Stack, {Brendan C.} and Dalsaso, {Thomas A.} and Christopher Lee and Lowe, {Val J.} and Hamilton, {Paul D.} and James Fletcher and Fernandez-Pol, {J. Albert}",
year = "1999",
language = "English (US)",
volume = "19",
pages = "5503--5510",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 C",

}

TY - JOUR

T1 - Overexpression of MPS antigens by squamous cell carcinomas of the head and neck immunohistochemical and serological correlation with FDG positron emission tomography

AU - Stack, Brendan C.

AU - Dalsaso, Thomas A.

AU - Lee, Christopher

AU - Lowe, Val J.

AU - Hamilton, Paul D.

AU - Fletcher, James

AU - Fernandez-Pol, J. Albert

PY - 1999

Y1 - 1999

N2 - Survival from advanced primary or recurrent Squamous Cell Carcinoma (SCC) of the head and neck (H and N) is poor. More accurate defection of primary tumors and recurrence may provide ways to improve survival. No standard serum tumor marker is routinely used for surveillance of SCC-H and N. In this paper, we evaluated the performance characteristics of the MPS-H tumor marker test for the quantitative measurement of 'MPS-H' heat-generated immunoreactive proteins and assessed the clinical utility of this marker in the detection and monitoring of SCC-H and N. In approximately 92% of the subjects having no evidence of SCC-H and N, the MPS-H levels were lower than 15 ng/mL. In 76% of patients having SCC-H and N at various stages (T1-T4) the MPS-H level was > 15 ng/ml (range: 20-200 ng/mL). In addition, we found a statistically significant correlation between PET positive cases and high MPS-H serum levels in SCC-H and N patients with recurrent disease. These results suggest that MPS-H may provide an initial screening test that would allow for selective PET imaging in these patients. Furthermore, we found that there was greater expression of MPS-1 in tumors of higher histological grades. Thus, in tumors with more histological agressiveness there is more MPS-I, indicating the potential usefulness of this marker in prognosis for SSC-H and N. Considering the immunohistochemical, serological, and FDG-PET data presented here, and the compelling need to expedite the early diagnosis of primary and recurrent epithelial malignancies of the head and neck, we are further evaluating the system of MPS antigens in a large patient population as a tool for the early serologic and histologic diagnosis of SCC-H and N.

AB - Survival from advanced primary or recurrent Squamous Cell Carcinoma (SCC) of the head and neck (H and N) is poor. More accurate defection of primary tumors and recurrence may provide ways to improve survival. No standard serum tumor marker is routinely used for surveillance of SCC-H and N. In this paper, we evaluated the performance characteristics of the MPS-H tumor marker test for the quantitative measurement of 'MPS-H' heat-generated immunoreactive proteins and assessed the clinical utility of this marker in the detection and monitoring of SCC-H and N. In approximately 92% of the subjects having no evidence of SCC-H and N, the MPS-H levels were lower than 15 ng/mL. In 76% of patients having SCC-H and N at various stages (T1-T4) the MPS-H level was > 15 ng/ml (range: 20-200 ng/mL). In addition, we found a statistically significant correlation between PET positive cases and high MPS-H serum levels in SCC-H and N patients with recurrent disease. These results suggest that MPS-H may provide an initial screening test that would allow for selective PET imaging in these patients. Furthermore, we found that there was greater expression of MPS-1 in tumors of higher histological grades. Thus, in tumors with more histological agressiveness there is more MPS-I, indicating the potential usefulness of this marker in prognosis for SSC-H and N. Considering the immunohistochemical, serological, and FDG-PET data presented here, and the compelling need to expedite the early diagnosis of primary and recurrent epithelial malignancies of the head and neck, we are further evaluating the system of MPS antigens in a large patient population as a tool for the early serologic and histologic diagnosis of SCC-H and N.

KW - Metallopanstimulin

KW - Ribosomal S27 protein

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0033367063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033367063&partnerID=8YFLogxK

M3 - Article

C2 - 10697607

AN - SCOPUS:0033367063

VL - 19

SP - 5503

EP - 5510

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 C

ER -